Granted Patent
B2
US 12,397,038 · App. 16/767,392 · Granted Aug 26, 2025
Ubiquitous antigens for treatment of autoimmune or inflammatory diseases
Assignee:
UTI Limited Partnership
A61K38/1774A61K9/143A61K33/26A61K38/1719A61K38/415A61K39/0008A61K47/60A61P25/00A61P25/28C07K14/4713A61K2035/122A61K2039/55555A61K2039/605
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are methods for treating an autoimmune or inflammatory disease in a patient, comprising administering a composition comprising: a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2 353-367 , PDC-E2 72-86 , and PDC-E2 422-436 for DRB3*0202; PDC-E2 353-367 , PDC-E2 80-94 , and PDC-E2 535-549 for DRB5*0101; PDC-E2 629-648 , PDC-E2 122-135 , and PDC-E2 249-263 for DRB4*0101; and PDC-E2 249-263 for DRB1*0801; and b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers; wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.
Claims (24)
1. A method for treating an autoimmune or inflammatory disease in a patient in need thereof, comprising administering to the patient a composition comprising:
a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2 353-367 , PDC-E2 72-86 , and PDC-E2 422-436 for DRB3*0202; PDC-E2 353-367 , PDC-E2 80-94 , and PDC-E2 535-549 for DRB5*0101; PDC-E2 629-648 , PDC-E2 122-135 , and PDC-E2 249-263 for DRB4*0101; and PDC-E2 249-263 for DRB1*0801; and
b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers;
wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and
wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.
2. The method of claim 1 , wherein the nanoparticle core is a metal or metal oxide.
3. The method of claim 2 , wherein the metal is iron.
4. The method of claim 2 , wherein the metal oxide is iron oxide.
5. The method of claim 1 , wherein the diameter is between about 5 nanometers and about 50 nanometers.
6. The method of claim 5 , wherein the diameter is between about 5 nanometers and about 25 nanometers.
7. The method of claim 1 , wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of at least 10:1.
8. The method of claim 1 , wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at an antigen-MHC to nanoparticle core ratio of no more than about 150:1.
9. The method of claim 1 , wherein the plurality of antigen-MHCs is coupled to the nanoparticle core at a density from about 0.4 to about 13 antigen-MHCs per 100 nm 2 of nanoparticle core surface area.
10. The method of claim 1 , wherein the antigen-MHCs are covalently coupled to the nanoparticle core.
11. The method of claim 1 , wherein the antigen-MHCs are coupled to the nanoparticle core by a polyethylene glycol (PEG) linker having a mass of less than about 5 kilodaltons.
12. The method of claim 1 , wherein the nanoparticle core further comprises a biocompatible coating.
13. The method of claim 1 , wherein the ubiquitous autoantigen is selected from the group consisting of: PDC-E2 422-436 and PDC-E2 80-94 .
14. The method of claim 1 further comprising a pharmaceutically acceptable stabilizer, excipient, diluent, or combination thereof.
15. The method of claim 1 , formulated for intravenous administration.
16. A method of treating an autoimmune or inflammatory disease in an individual comprising administering to an individual a composition comprising:
a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2353-367, PDC-E2 72-86 , and PDC-E2 422-436 for DRB3*0202; PDC-E2 353-367 , PDC-E2 80-94 , and PDC-E2 535-549 for DRB5*0101; PDC-E2 629-648 , PDC-E2122-135, and PDC-E2 249-263 for DRB4*0101; and PDC-E2 249-263 for DRB1*0801; and
b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers;
wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and
wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 7, 2020
From: SANTAMARIA, PEDRO
To: UTI LIMITED PARTNERSHIP
Reel/Frame 053143/0201 →
Continuity (4)
Provisional Application
62591921
· Nov 29, 2017
Provisional Application
62636520
· Feb 28, 2018
Provisional Application
62641607
· Mar 12, 2018
References Cited (400)
US 4367110A
· Yoshikawa
· 1983
[cited by applicant]
US 4414148A
· Jansen
· 1983
[cited by applicant]
US 4452901A
· Gordon
· 1984
[cited by applicant]
US 4478946A
· Van der Merwe
· 1984
[cited by applicant]
US 4554101A
· Hopp
· 1985
[cited by applicant]
US 4569789A
· Blattler
· 1986
[cited by applicant]
US 4589071A
· Yamamuro
· 1986
[cited by applicant]
US 4589330A
· Teron
· 1986
[cited by applicant]
US 4659839A
· Nicolotti
· 1987
[cited by applicant]
US 4671958A
· Rodwell
· 1987
[cited by applicant]
US 4680338A
· Sundoro
· 1987
[cited by applicant]
US 4699784A
· Shih
· 1987
[cited by applicant]
US 4818542A
· Deluca
· 1989
[cited by applicant]
US 4859839A
· Tetelman
· 1989
[cited by applicant]
US 5258499A
· Konigsberg
· 1993
[cited by applicant]
US 5543391A
· Yatvin
· 1996
[cited by applicant]
US 5676926A
· Platzek
· 1997
[cited by applicant]
US 5676928A
· Klaveness
· 1997
[cited by applicant]
US 5731168A
· Carter
· 1998
[cited by applicant]
US 5807706A
· Carter
· 1998
[cited by applicant]
US 5821333A
· Carter
· 1998
[cited by applicant]
US 5840839A
· Wang
· 1998
[cited by applicant]
US 6103379A
· Margel
· 2000
[cited by applicant]
US 6387498B1
· Coulter
· 2002
[cited by applicant]
US 6651655B1
· Licalsi
· 2003
[cited by applicant]
US 6688494B2
· Pozarnsky
· 2004
[cited by applicant]
US 6712997B2
· Won
· 2004
[cited by applicant]
US 6797514B2
· Berenson
· 2004
[cited by applicant]
US 6846474B2
· Nayfeh
· 2005
[cited by applicant]
US 6929675B1
· Bunge
· 2005
[cited by applicant]
US 7060121B2
· Lin
· 2006
[cited by applicant]
US 7090973B1
· Breton
· 2006
[cited by applicant]
US 7183065B2
· Braun
· 2007
[cited by applicant]
US 7285289B2
· Nagy
· 2007
[cited by applicant]
US 7326399B2
· Zhou
· 2008
[cited by applicant]
US 7332586B2
· Franzen
· 2008
[cited by applicant]
US 7361733B2
· Hershberg
· 2008
[cited by applicant]
US 7572631B2
· Berenson
· 2009
[cited by applicant]
US 7642228B2
· Carter
· 2010
[cited by applicant]
US 7695936B2
· Carter
· 2010
[cited by applicant]
US 7785801B2
· Tuereci
· 2010
[cited by applicant]
US 7795224B2
· Eisenbach
· 2010
[cited by applicant]
US 7812116B2
· Bae
· 2010
[cited by applicant]
US 7816814B1
· Hennessy
· 2010
[cited by applicant]
US 8216805B2
· Carter
· 2012
[cited by applicant]
US 8354110B2
· Santamaria
· 2013
[cited by applicant]
US 8679785B2
· Carter
· 2014
[cited by applicant]
US 8835144B2
· Jiang
· 2014
[cited by applicant]
US 9149440B2
· Turos
· 2015
[cited by applicant]
US 9511151B2
· Santamaria
· 2016
[cited by applicant]
US 9603948B2
· Santamaria
· 2017
[cited by applicant]
US 20030068363A1
· Clark
· 2003
[cited by applicant]
US 20030124149A1
· Shalaby
· 2003
[cited by applicant]
US 20040115216A1
· Schneck
· 2004
[cited by applicant]
US 20040137642A1
· Erfle
· 2004
[cited by applicant]
US 20040197304A1
· Chen
· 2004
[cited by applicant]
US 20040224402A1
· Bonyhadi
· 2004
[cited by applicant]
US 20050003431A1
· Wucherpfennig
· 2005
[cited by applicant]
US 20050118102A1
· Xiang
· 2005
[cited by applicant]
US 20050129617A1
· Tan
· 2005
[cited by applicant]
US 20050202032A1
· Kaufman
· 2005
[cited by applicant]
US 20060246524A1
· Bauer
· 2006
[cited by examiner]
US 20070054337A1
· Ferning
· 2007
[cited by applicant]
US 20070059775A1
· Hultman
· 2007
[cited by applicant]
US 20070129307A1
· Tan
· 2007
[cited by applicant]
US 20070154953A1
· Brunner
· 2007
[cited by applicant]
US 20090258355A1
· Maye
· 2009
[cited by applicant]
US 20100061984A1
· Greene
· 2010
[cited by applicant]
US 20100095544A1
· Haseloh
· 2010
[cited by applicant]
US 20110059121A1
· Santamaria
· 2011
[cited by applicant]
US 20110250146A1
· Zhang
· 2011
[cited by applicant]
US 20110318380A1
· Brix
· 2011
[cited by applicant]
US 20120093934A1
· Santamaria
· 2012
[cited by applicant]
US 20130128138A1
· Kuo
· 2013
[cited by applicant]
US 20130171179A1
· Burrows
· 2013
[cited by applicant]
US 20130302421A1
· Santamaria
· 2013
[cited by applicant]
US 20140105980A1
· Santamaria
· 2014
[cited by applicant]
US 20150150996A1
· Miller
· 2015
[cited by applicant]
US 20150250871A1
· Santamaria
· 2015
[cited by applicant]
US 20150374815A1
· Kishimoto
· 2015
[cited by applicant]
US 20160068613A1
· Regula
· 2016
[cited by applicant]
US 20160271237A1
· Santamaria
· 2016
[cited by applicant]
US 20170333540A1
· Santamaria
· 2017
[cited by applicant]
US 20180127481A1
· Santamaria
· 2018
[cited by applicant]
US 20190134171A1
· Santamaria
· 2019
[cited by applicant]
US 20200057048A1
· Santamaria
· 2020
[cited by applicant]
US 20210145949A1
· Santamaria
· 2021
[cited by applicant]
US 20210205470A1
· Santamaria
· 2021
[cited by applicant]
US 20220401534A1
· Santamaria
· 2022
[cited by applicant]
US 20230355730A1
· Santamaria
· 2023
[cited by applicant]
US 20240201171A1
· Santamaria
· 2024
[cited by applicant]
US 20240299536A1
· Santamaria
· 2024
[cited by applicant]
CA 2517097
· 2004
[cited by applicant]
CA 2717719
· 2009
[cited by applicant]
CA 2868551
· 2013
[cited by applicant]
CN 101678090
· 2010
[cited by applicant]
EP 0188256
· 1986
[cited by applicant]
EP 1088256
· 2001
[cited by applicant]
EP 2131856
· 2009
[cited by applicant]
EP 2614834
· 2013
[cited by applicant]
EP 2621523
· 2013
[cited by applicant]
EP 3065771
· 2016
[cited by applicant]
EP 3067366
· 2016
[cited by applicant]
EP 3269384
· 2018
[cited by applicant]
EP 3291832
· 2018
[cited by applicant]
EP 3539564
· 2019
[cited by applicant]
JP 2003231698
· 2003
[cited by applicant]
JP 2005538083
· 2005
[cited by applicant]
JP 2006522319
· 2006
[cited by applicant]
JP 2007508503
· 2007
[cited by applicant]
JP 2008514686
· 2008
[cited by applicant]
JP 2010522695
· 2010
[cited by applicant]
JP 2012505249
· 2012
[cited by applicant]
JP 2013538208
· 2013
[cited by applicant]
JP 2015063616
· 2015
[cited by applicant]
KR 20120100840
· 2012
[cited by applicant]
WO 1990007339
· 1990
[cited by applicant]
WO 1992018150
· 1992
[cited by applicant]
WO 1993001716
· 1993
[cited by applicant]
WO 1993016725
· 1993
[cited by applicant]
WO 1994009823
· 1994
[cited by applicant]
WO 1996018105
· 1996
[cited by applicant]
WO 1998006749
· 1998
[cited by applicant]
WO 1999014236
· 1999
[cited by applicant]
WO 1999042597
· 1999
[cited by applicant]
WO 1999064926
· 1999
[cited by applicant]
WO 2000043662
· 2000
[cited by applicant]
WO 2000067788
· 2000
[cited by applicant]
WO 2001024764
· 2001
[cited by applicant]
WO 2002080963
· 2002
[cited by applicant]
WO 2004006951
· 2004
[cited by applicant]
WO 2004076909
· 2004
[cited by applicant]
WO 2004078909
· 2004
[cited by applicant]
WO 2005033267
· 2005
[cited by applicant]
WO 2005036035
· 2005
[cited by applicant]
WO 2006016113
· 2006
[cited by applicant]
WO 2006037979
· 2006
[cited by applicant]
WO 2006054806
· 2006
[cited by applicant]
WO 2006080951
· 2006
[cited by applicant]
WO 2007024026
· 2007
[cited by applicant]
WO 2008051245
· 2008
[cited by applicant]
WO 2008109852
· 2008
[cited by applicant]
WO 2008118861
· 2008
[cited by applicant]
WO 2009003492
· 2009
[cited by applicant]
WO 2009031258
· 2009
[cited by applicant]
WO 2009040811
· 2009
[cited by applicant]
WO 2009064273
· 2009
[cited by applicant]
WO 2009078799
· 2009
[cited by applicant]
WO 2009094273
· 2009
[cited by applicant]
WO 2009111588
· 2009
[cited by applicant]
WO 2009126835
· 2009
[cited by applicant]
WO 2010025324
· 2010
[cited by applicant]
WO 2010027827
· 2010
[cited by applicant]
WO 2010037395
· 2010
[cited by applicant]
WO 2010037397
· 2010
[cited by applicant]
WO 2010042876
· 2010
[cited by applicant]
WO 2010080032
· 2010
[cited by applicant]
WO 2010085509
· 2010
[cited by applicant]
WO 2011073685
· 2011
[cited by applicant]
WO 2011104497
· 2011
[cited by applicant]
WO 2012012874
· 2012
[cited by applicant]
WO 2012031258
· 2012
[cited by applicant]
WO 2012041968
· 2012
[cited by applicant]
WO 2012062904
· 2012
[cited by applicant]
WO 2012121528
· 2012
[cited by applicant]
WO 2013043662
· 2013
[cited by applicant]
WO 2013072051
· 2013
[cited by applicant]
WO 2013103438
· 2013
[cited by applicant]
WO 2013144811
· 2013
[cited by applicant]
WO 2014080286
· 2014
[cited by applicant]
WO 2014096015
· 2014
[cited by applicant]
WO 2015063616
· 2015
[cited by applicant]
WO 2016081854
· 2016
[cited by applicant]
WO 2016097334
· 2016
[cited by applicant]
WO 2016145605
· 2016
[cited by applicant]
WO 2016146505
· 2016
[cited by applicant]
WO 2016160721
· 2016
[cited by applicant]
WO 2016193299
· 2016
[cited by applicant]
WO 2016198932
· 2016
[cited by applicant]
WO 2017044672
· 2017
[cited by applicant]
WO 2018087597
· 2018
[cited by applicant]
WO 2018185564
· 2018
[cited by applicant]
WO 2019106435
· 2019
[cited by applicant]
Lieo, A., et al. Semin. Liver. Dis.; 34(3):273-284 (Year: 2014).
[cited by examiner]
Schaefer, W. et al., “Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry”, MAbs., 8(1):49-55, (2016).
[cited by applicant]
Umeshappa, C. et al., “Suppression of A Broad Spectrum of Liver Autoimmune Pathologies by Single Peptide-MHC-Based Nanomedicines”, Nat Commun., 10(1):2150, (2019).
[cited by applicant]
GenBank Accession No. AAC14923.1, “T cell receptor alpha chain [
[cited by applicant]
t Hart, B. et al., “Modelling of Multiple Sclerosis: Lessons Learned in a Non-Human Primate”, Lancet Neurol., 3(10):588-97, (2004).
[cited by applicant]
Aichele, P. et al., “Peptide-induced T-cell Tolerance to Prevent Autoimmune Diabetes in a Transgenic Mouse Model”, Proc Natl Acad Sci USA, 91(2):444-8, (1994).
[cited by applicant]
Altman, J. et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes”, Science, 274(5284):94-6, (1996).
[cited by applicant]
Altschul, S. et al., “Basic Local Alignment Search Tool”, J Mol Biol., 215(3):403-10, (1990).
[cited by applicant]
Amrani, A. et al., “Expansion of the Antigenic Repertoire of a Single T Cell Receptor Upon T Cell Activation”, J Immunol., 167(2):655-66, (2001).
[cited by applicant]
Amrani, A. et al., “Progression of Autoimmune Diabetes Driven by Avidity Maturation of a T-cell Population,” Nature, 406(6797):739-42, (2000).
[cited by applicant]
Anderson, B. et al., “Prevalent CD8(+) T Cell Response Against One peptide/MHC Complex in Autoimmune Diabetes”, Proc Natl Acad Sci USA, 96(16):9311-6, (1999).
[cited by applicant]
Anderton, S. et al., “Hierarchy in the Ability of T Cell Epitopes to Induce Peripheral Tolerance to Antigens From Myelin”, Eur J Immunol., 28(4):1251-61, (1998).
[cited by applicant]
Anonymous, Diabetes Prevention Trial—Type 1 Diabetes Study Group, “Effects of Insulin in Relatives of Patients With Type 1 Diabetes Mellitus”, N Engl J Med., 346(22):1685-91, (2002).
[cited by applicant]
Anonymous, Website article from kidshealth.org/PageManager.jsp?dn=KidsHealth&lic=1&ps=107&cat_id=139&article; downloaded Nov. 9, 2010: 2 pages total.
[cited by applicant]
Appay, V. et al., “HIV-specific CD8(+) T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function”, J Exp Med., 192(1):63-72, (2000).
[cited by applicant]
Asai, H. et al., “Co-introduced Functional CCR2 Potentiates in Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-specific T-cell”, PLoS One, 8(2):e56820, (2013).
[cited by applicant]
Azuma, M. et al., “T Cell Costimulation and Diseases,” Kokubyo Gakkai Zasshi, 67(3):233-9, (2000).
[cited by applicant]
Babbe, H. et al., “Clonal Expansions of CD8(+) T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction”, J Exp Med., 192(3):393…
[cited by applicant]
Bacchetta, R. et al., “High Levels of Interleukin 10 Production in Vivo Are Associated With Tolerance in SCID Patients Transplanted With HLA Mismatched Hematopoietic Stem Cells ”, J Exp Med., 179(2):493-502, (1994).
[cited by applicant]
Bachmann, M. et al., “Developmental Regulation of Lck Targeting to the CD8 Coreceptor Controls Signaling in Naive and Memory T Cells”, J Exp Med., 189(10):1521-30, (1999).
[cited by applicant]
Bahcetepe, N. et al., “The Role of HLA Antigens in the Aetiology of Psoriasis”, Med Glas (Zenica), 10(2):339-42, (2013).
[cited by applicant]
Bailey-Bucktrout, S. et al., “Self-antigen-driven Activation Induces Instability of Regulatory T Cells During an Inflammatory Autoimmune Response”, Immunity, 39(5):949-62, (2013).
[cited by applicant]
Baker, D. et al., “Critical Appraisal of Animal Models of Multiple Sclerosis”, Mult Scler., 17(6):647-57, (2011).
[cited by applicant]
Bakker, A. et al., “MHC Multimer Technology: Current Status and Future Prospects”, Curr Opin Immunol., 17(4):428-33, (2005).
[cited by applicant]
Barber, D. et al., “Restoring Function in Exhausted CD8 T Cells During Chronic Viral Infection”, Nature, 439(7077):682-7, (2006).
[cited by applicant]
Becker, T. et al., “Interleukin 15 Is Required for Proliferative Renewal of Virus-Specific Memory CD8 T Cells”, J Exp Med., 195(12):1541-8, (2002).
[cited by applicant]
Behan, P. et al., “The Sad Plight of Multiple Sclerosis Research (Low on Fact, High on Fiction): Critical Data to Support It Being a Neurocristopathy”, Inflammopharmacology, 18(6):265-90, (2010).
[cited by applicant]
Chen, Q. et al., “IL-2 Controls the Stability of Foxp3 Expression in TGF-beta-induced Foxp3+ T Cells in Vivo”, J Immunol., 186(11):6329-37, (2011).
[cited by applicant]
Choudhuri, K. et al., “Signaling Microdomains in T Cells”, FEBS Lett., 584(24):4823-31, (2010).
[cited by applicant]
Cirillo, C. et al., “S100B Protein in the Gut: The Evidence for Enteroglial-Sustained Intestinal Inflammation”, World J Gastroenterol., 17(10):1261-6, (2011).
[cited by applicant]
Clemente Casares, J. “pMHC-Class II Nanovaccine to Treat Autoimmune Diseases”, Doctor of Philosophy Thesis, Calgary University, Alberta, Canada, 391 pages, retrieved from: http://theses.ucalgary.ca/handle/11023/1589; (2…
[cited by applicant]
Clemente-Casares, X. et al., “Expanding Antigen-Specific Regulatory Networks to Treat Autoimmunity”, Nature, 530(7591):434-40, (2016).
[cited by applicant]
Clemente-Casares, X. et al., “Peptide-MHC-based Nanovaccines for the Treatment of Autoimmunity: A “One Size Fits All” Approach?”, J Mol Med., 89(8):733-42, (2011).
[cited by applicant]
Cnop, M. et al., “Mechanisms of Pancreatic Beta-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities”, Diabetes, 54(Suppl 2):S97-S107, (2005).
[cited by applicant]
Constantinescu, C. et al., “Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS)”, Br J Pharmacol., 164(4):1079-106, (2011).
[cited by applicant]
Corrigall, V. et al., “Autoantigens and Immune Pathways in Rheumatoid Arthritis”, Grit Rev Immunol., 22(4):281-93, (2002).
[cited by applicant]
Croxford, A. et al., “Mouse Models for Multiple Sclerosis: Historical Facts and Future Implications”, Biochim Biophy Acta., 1812(2):177-83, (2011).
[cited by applicant]
Cuív, P. et al., “Draft Genome Sequence of Bacteroides Vulgatus PC510, a Strain Isolated From Human Feces”, J Bacteriol., 193(15):4025-6, (2011 ).
[cited by applicant]
Culina, S. et al., “Antigen-Based Immune Therapeutics for Type 1 Diabetes: Magic Bullets or Ordinary Blanks?”, Clin Dev Immunol., 2011:286248, (2011).
[cited by applicant]
Daperno, M. et al., “Results of the 2nd Part Scientific Workshop of the ECCO. II: Measures and Markers of Prediction to Achieve, Detect, and Monitor Intestinal Healing in Inflammatory Bowel Disease”, J Crohns Colitis., …
[cited by applicant]
Dave, M. et al., “Mucosal Healing in Inflammatory Bowel Disease-A True Paradigm of Success?”, Gastroenterol hepatol., 8(1):29-38, (2012).
[cited by applicant]
Davies, R. et al., “Engineered Particle Surfaces”, Adv Mat., 10(15):1264-70, (1998).
[cited by applicant]
De Plaen, E. et al., “Immunogenic (Tum−) Variants of Mouse Tumor P815: Cloning of the Gene of Tum− Antigen P91A and Identification of the Tum− Mutation”, Proc Natl Acad Sci USA, 85(7):2274-8, (1988).
[cited by applicant]
Denic, A. et al., “The Relevance of Animal Models in Multiple Sclerosis Research”, Pathophysiology, 18(1):21-9, (2011).
[cited by applicant]
Desreumaux, P. et al., “Safety and Efficacy of Antigen-Specific Regulatory T-cell Therapy for Patients With Refractory Crohn's Disease”, Gastroenterology, 143(5):1207-17, (2012).
[cited by applicant]
Flad, T. et al., “Development of an MHC-class I Peptide Selection Assay Combining Nanoparticle Technology and Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry”, J Immunol Methods, 283(1-2):205-13, (2003).
[cited by applicant]
Jarchum, I. et al., “Identification of Novel IGRP Epitopes Targeted in Type 1 Diabetes Patients”, Clin Immunol., 127(3):359-65, (2008).
[cited by applicant]
Jarchum, I. et al., “In Vivo Cytotoxicity of Insulin-Specific CD8+ T-cells in HLA-A*0201 Transgenic NOD Mice”, Diabetes, 56(10):2551-60, (2007).
[cited by applicant]
Jarius, S. et al., “Mechanisms of Disease: Aquaporin-4 Antibodies in Neuromyelitis Optica”, Nat Clin Pract Neurol., 4(4):202-14, (2008).
[cited by applicant]
Jokerst, J. et al., “Nanoparticle PEGylation for Imaging and Therapy”, Nanomedicine (Lond.), 6(4):715-28, (2011).
[cited by applicant]
Judge, A. et al., “Interleukin 15 Controls Both Proliferation and Survival of a Subset of Memory-Phenotype CD8(+) T Cells”, J Exp Med., 196(7):935-46, (2002).
[cited by applicant]
Jun, H. et al., “A New Look at Viruses in Type 1 Diabetes”, Diab Met Res., 19(1):8-31, (2003).
[cited by applicant]
Jurewicz, A. et al., “MHC Class I-restricted Lysis of Human Oligodendrocytes by Myelin Basic Protein Peptide-Specific CD8 T Lymphocytes”, J Immunol., 160(6):3056-9, (1998).
[cited by applicant]
Kamanaka, M. et al., “Expression of interleukin-10 in Intestinal Lymphocytes Detected by an interleukin-10 Reporter Knockin Tiger Mouse”, Immunity, 25(6):941-52, (2006).
[cited by applicant]
Kamikura, Y. et al., “Adhesion, Costimulatory Molecule, Trafficking, Homing: Cancer Immunotherapy and Costimulatory Molecule”, Ann Rev., Immunity, 162:2-13, (2004).
[cited by applicant]
Kappos, L. et al., “Induction of a Non-Encephalitogenic Type 2 T Helper-Cell Autoimmune Response in Multiple Sclerosis After Administration of an Altered Peptide Ligand in a Placebo-Controlled, Randomized Phase II Trial…
[cited by applicant]
Karin, N. et al., “Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Fa…
[cited by applicant]
Karlin, S. et al., “Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences”, Proc Natl Acad Sci USA, 90(12):5873-7, (1993).
[cited by applicant]
Karounos, D. et al., “Metabolically Inactive Insulin Analog Prevents Type I Diabetes in Prediabetic NOD Mice”, J Clin Invest., 100(6):1344-8, (1997).
[cited by applicant]
Kent, S. et al., “Expanded T Cells From Pancreatic Lymph Nodes of Type 1 Diabetic Subjects Recognize an Insulin Epitope”, Nature, 435(7039):224-8, (2005).
[cited by applicant]
Keymeulen, B. et al., “Insulin Needs After CD3-antibody Therapy in New-Onset Type 1 Diabetes”, N Engl J Med., 352(25):2598-608, (2005).
[cited by applicant]
Kim, S. et al., “Induction and Visualization of Mucosal Memory CD8 T Cells Following Systemic Virus Infection”, J Immunol., 163(8):4125-32, (1999).
[cited by applicant]
Kita, H. et al., “Quantitative and Functional Analysis of PDC-E2-specific Autoreactive Cytotoxic T Lymphocytes in Primary Biliary Cirrhosis”, J Clin Invest., 109(9):1231-40, (2002).
[cited by applicant]
Komai-Koma, M. et al., “TLR2 Is Expressed on Activated T Cells as a Costimulatory Receptor”, Proc Natl Acad Sci USA, 181(9):3829-34, (2004).
[cited by applicant]
Longhi, M. et al., “Autoantigen-specific Regulatory T Cells, a Potential Tool for Immune-Tolerance Reconstitution in type-2 Autoimmune Hepatitis”, Hepatology, 53(2):536-47, (2011).
[cited by applicant]
Lowery, A. et al., “Immunonanoshells for Targeted Photothermal Ablation of Tumor Cells”, Int J Nanomedicine, 1(2):149-54, (2006).
[cited by applicant]
Lupas, A., “Coiled Coils: New Structures and New Functions”, TIB 21, 375-82, (1996).
[cited by applicant]
Ma, Z. et al., “TCR Triggering by pMHC Ligands Tethered on Surfaces via Poly(ethylene Glycol) Depends on Polymer Length”, PLoS One, 9(11):e112292, (2014).
[cited by applicant]
Mallone, R. et al., “CD8+ T-cell Responses Identify Beta-Cell Autoimmunity in Human Type 1 Diabetes”, Diabetes, 56(3):613-21, (2007).
[cited by applicant]
Mallone, R. et al., “T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives”, Clin Dev Immunol., 2011:513210, (2011).
[cited by applicant]
Marée, A. et al., “Modeling Competition Among Autoreactive CD8+ T Cells in Autoimmune Diabetes: Implications for Antigen-Specific Therapy”, Int Immunol., 18(7):1067-77, (2006).
[cited by applicant]
Mars, L. et al., “CD8 T Cell Responses to Myelin Oligodendrocyte Glycoprotein-Derived Peptides in Humanized HLA-A*0201-transgenic Mice”. J Immunol., 179(8):5090-8, (2007).
[cited by applicant]
Marsh, S. et al., “Nomenclature for Factors of the HLA System, Update Oct. 2010”, Tissue Antigens, 77(4):349-54, (2011).
[cited by applicant]
Martínez-Martín, N et al., “Cooperativity Between T Cell Receptor Complexes Revealed by Conformational Mutants of CD3epsilon”, Sci Signal., 2(83):ra43, (2009).
[cited by applicant]
Marwaha, A. et al., “Cutting Edge: Increased IL-17-secreting T Cells in Children With New-Onset Type 1 Diabetes”, J Immunol., 185(7):3814-8, (2010).
[cited by applicant]
Mazzarella, G., “Effector and Suppressor T Cells in Celiac Disease”, World J Gastroenterol., 21(24):7349-56, (2015).
[cited by applicant]
McCarthy, D. et al., “Mouse Models of Multiple Sclerosis: Experimental Autoimmune Encephalomyelitis and Theiler's Virus-Induced Demyelinating Disease”, Methods Mol Biol., 900:281-401, (2012).
[cited by applicant]
McClymont, S. et al., “Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients With Type 1 Diabetes”, J Immunol., 186(7):3918-26, (2011).
[cited by applicant]
McKeithan, T., “Kinetic Proofreading in T-cell Receptor Signal Transduction”, Proc Natl Acad Sci USA, 92(11):5042-6, (1995).
[cited by applicant]
McLarnon, A., “IBD: Regulatory T-cell Therapy Is a Safe and Well-Tolerated Potential Approach for Treating Refractory Crohn's Disease”, Nat Rev Gastroenterol Hepatol., 9(10):559, (2012).
[cited by applicant]
Mei, X. et al., Chemical Industry Press, Biotechnology Pharmaceutic Preparation: Foundation and Application: 199, (2004).
[cited by applicant]
Merchant, A. et al., “An Efficient Route to Human Bispecific IgG”, Nat Biotechnol., 16(7):677-81, (1998).
[cited by applicant]
Mescher, M. et al., “Signals Required for Programming Effector and Memory Development by CD8+ T Cells”, Immunol Rev., 211:81-92, (2006).
[cited by applicant]
Mestas, J. et al., “Of Mice and Not Men: Differences Between Mouse and Human Immunology”, J Immunol., 172(5):2731-8, (2004).
[cited by applicant]
Metzler, B. et al., “Inhibition of Experimental Autoimmune Encephalomyelitis by Inhalation but Not Oral Administration of the Encephalitogenic Peptide: Influence of MHC Binding Affinity”, Int Immunol., 5(9):1159-65, (19…
[cited by applicant]
Miguel-Sancho, N. et al., “Development of Stable, Water-Dispersible, and Biofunctionalizable Superparamagnetic Iron Oxide Nanoparticles”, Chem Mat., 23(11):2795-802, (2011).
[cited by applicant]
Miller, S. et al., “The Induction of Cell-Mediated Immunity and Tolerance With Protein Antigens Coupled to Syngeneic Lymphoid Cells”, J Exp Med., 149(3):758-66, (1979).
[cited by applicant]
Miyara, M. et al., “Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor”, Immunity, 30(6):899-911, (2009).
[cited by applicant]
Mondini, S. et al., “One-Step Synthesis and Functionalization of Hydroxyl-Decorated Magnetite Nanoparticles”, J Colloid Interface Sci., 322(1):173-9, (2008).
[cited by applicant]
Moore, A. et al., “Tracking the Recruitment of Diabetogenic CD8+ T-cells to the Pancreas in Real Time”, Diabetes, 53(6):1459-66, (2004).
[cited by applicant]
Mukherjee, R. et al., “Identification of CD4+ T Cell-Specific Epitopes of Islet-Specific glucose-6-phosphatase Catalytic Subunit-Related Protein: A Novel Beta Cell Autoantigen in Type 1 Diabetes”, J Immunol., 174(9):530…
[cited by applicant]
Musacchio, T. et al., “PEG-PE Micelles Loaded With Paclitaxel and Surface-Modified by a PBR-ligand: Synergistic Anticancer Effect”, Mol Pharm., 6(2):468-79, (2009).
[cited by applicant]
Nakayama, M. et al., “Prime Role for an Insulin Epitope in the Development of Type 1 Diabetes in NOD Mice”, Nature, 435(7039):220-3, (2005).
[cited by applicant]
Nelson, J. et al., “6 Types of Asthma and How They're Treated”, Mother Nature Network, mnn.com, 4 pages, (2015).
[cited by applicant]
Noren, C. et al., “A General Method for Site-Specific Incorporation of Unnatural Amino Acids Into Proteins”, Science, 244(4901):182-8, (1989).
[cited by applicant]
Oh, S. et al., “IL-15/IL-15Ralpha-mediated Avidity Maturation of Memory CD8+ T Cells”, Proc Natl Acad Sci USA, 101:15154-9, (2004).
[cited by applicant]
Oleszak, E. et al., “Theiler's Virus Infection: A Model for Multiple Sclerosis,” Clin Microbiol Rev., 17(1):174-207, (2004).
[cited by applicant]
Onoda, T. et al., “Human CD4+ Central and Effector Memory T Cells Produce IL-21: Effect on Cytokine-Driven Proliferation of CD4+ T Cell Subsets”, Int Immunol., 19(10):1191-9, (2007).
[cited by applicant]
Ouyang, Q. et al., “Recognition of HLA Class I-restricted Beta-Cell Epitopes in Type 1 Diabetes”, Diabetes, 55(11):3068-74, (2006).
[cited by applicant]
Oyewumi, M. et al., Nano-microparticles as Immune Adjuvants: Correlating Particle Sizes and the Resultant Immune Responses, Expert Rev Vaccines, 9(9):1095-107, (2010).
[cited by applicant]
Pachner, A., “Experimental Models of Multiple Sclerosis”, Curr Opin Neurol., 24(3):291-9, (2011).
[cited by applicant]
Packard, T. et al., “COPD Is Associated With Production of Autoantibodies to a Broad Spectrum of Self-Antigens, Correlative With Disease Phenotype”, Immunol Res., 55(1-3):48-57, (2013).
[cited by applicant]
Pakula, A. et al., “Genetic Analysis of Protein Stability and Function”, Annu Rev Genet., 23:289-310, (1989).
[cited by applicant]
Palmer, J. et al., “Insulin Antibodies in Insulin-Dependent Diabetics Before Insulin Treatment”, Science, 222(4630):1337-9, (1983).
[cited by applicant]
Partch, R. et al., “Aerosol and Solution Modification of Particle-Polymer Interfaces”, J Adhesion, 67(1-4):259-76, (1998).
[cited by applicant]
Pascolo, S. et al., “HLA-A2.1-restricted Education and Cytolytic Activity of CD8(+) T Lymphocytes From beta2 Microglobulin (beta2m) HLA-A2.1 Monochain Transgenic H-2Db beta2m Double Knockout Mice”, J Exp Med., 185(12):2…
[cited by applicant]
Patel, J. et al., “Cationic Nanoparticles for Delivery of CpG Oligodeoxynucleotide and Ovalbumin: In Vitro and In Vivo Assessment”, J Biomed Nanotechnol., 3(1):97-106, (2007).
[cited by applicant]
Pekarek, K. et al., “Double-walled Polymer Microspheres for Controlled Drug Release”, Nature, 367(6460):258-60, (1994).
[cited by applicant]
Peng, S. et al., “Synthesis and Characterization of Monodisperse Hollow Fe3O4 Nanoparticles”, Angew Chem Int Ed Engl., 46(22):4155-8, (2007).
[cited by applicant]
Perrault, S. et al., “Mediating Tumor Targeting Efficiency of Nanoparticles Through Design”, Nano Lett, 9(5):1909-15, (2009).
[cited by applicant]
Petros, R. et al., Antibody Conjugation to PRINT Abstracts of Papers Am Chem Soc., 233(14):14, (2007).
[cited by applicant]
Pinkse, G. et al., “Autoreactive CD8 T Cells Associated With Beta Cell Destruction in Type 1 Diabetes”, Proc Natl Acad Sci USA, 102(51):18425-30, (2005).
[cited by applicant]
Ponder, J. et al., “Tertiary Templates for Proteins. Use of Packing Criteria in the Enumeration of Allowed Sequences for Different Structural Classes”, J Mol Biol., 193(4):775-91, (1987).
[cited by applicant]
Pot, C. et al., “Cutting Edge: IL-27 Induces the Transcription Factor c-Maf, Cytokine IL-21, and the Costimulatory Receptor ICOS That Coordinately Act Together to Promote Differentiation of IL-10− producing Tr1 Cells”, …
[cited by applicant]
Purton, J. et al., “Antiviral CD4+ Memory T Cells Are IL-15 Dependent ,” J Exp Med., 204(4):951-61, (2007).
[cited by applicant]
Quinn, M. et al., “How Do You Diagnose Rheumatoid Arthritis Early?”, Best Pract Res Clin Rheumatol., 15(1):49-66, (2001).
[cited by applicant]
Ransohoff, R., “Animal Models of Multiple Sclerosis: The Good, the Bad and the Bottom Line”, Nat Neurosci., 15(8):1074-7, (2012).
[cited by applicant]
Reijonen, H. et al., “Detection of GAD65-specific T-cells by Major Histocompatibility Complex Class II Tetramers in Type 1 Diabetic Patients and At-Risk Subjects”, Diabetes, 51(5):1375-82, (2002).
[cited by applicant]
Report to Congress, “Progress in Auotimmune Diseases Research”, U.S. DHHS, NIH, 146 pages, (2005).
[cited by applicant]
Riemekasten, G. et al., “Key Autoantigens in SLE”, Rheumatology (Oxford), 44(8):975-82, (2005).
[cited by applicant]
Roncarolo, M. et al., “Clinical Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation”, Immunol Rev., 241(1):145-63, (2011).
[cited by applicant]
Rossi, M. et al., “Intravenous or Intranasal Administration of Gliadin Is Able to Down-Regulate the Specific Immune Response in Mice”, Scand J Immunol., 50(2):177-82, (1999). (1999).
[cited by applicant]
Routsias, J. et al., “Autoimmune Response and Target Autoantigens in Sjogren's Syndrome”, Eur J Clin Invest., 40(11):1026-36, (2010).
[cited by applicant]
Saengruengrit, C. et al., “The Combined Magnetic Field and Iron oxide-PLGA Composite Particles: Effective Protein Antigen Delivery and Immune Stimulation in Dendritic Cells”, J Colloid Interface Sci., 520:101-11, (2018).
[cited by applicant]
Sahin, U. et al., “Human Neoplasms Elicit Multiple Specific Immune Responses in the Autologous Host”, Proc Natl Acad Sci USA, 92(25):11810-3, (1995).
[cited by applicant]
Sakaguchi, S. et al., “Foxp3+ CD25+ CD4+ Natural Regulatory T Cells in Dominant Self-Tolerance and Autoimmune Disease”, Immunol Rev., 212:8-27, (2006).
[cited by applicant]
Santamaria, P. et al., “Beta-cell-cytotoxic CD8+ T Cells From Nonobese Diabetic Mice Use Highly Homologous T Cell Receptor Alpha-Chain CDR3 Sequences”, J Immunol., 154(5):2494-503, (1995).
[cited by applicant]
Santamaria, P. et al., “Characterization of T Lymphocytes Infiltrating Human Pancreas Allograft Affected by Isletitis and Recurrent Diabetes”, Diabetes, 41(1):53-61, (1992).
[cited by applicant]
Santamaria, P. et al., “Skewed T-cell Receptor Usage and Junctional Heterogeneity Among Isletitis Alpha Beta and Gamma Delta T-cells in Human IDDM [Corrected]”, Diabetes, 43(4):599-606, (1994).
[cited by applicant]
Santamaria, P., “Effector Lymphocytes in Autoimmunity”, Curr Opin Immunol., 13(6):663-9, (2001).
[cited by applicant]
Santamaria, P., “The Long and Winding Road to Understanding and Conquering Type 1 Diabetes”, Immunity, 32(4):437-45, (2010).
[cited by applicant]
Saragovi, H. et al., “Small Molecule and Protein-Based Neurotrophic Ligands: Agonists and Antagonists as Therapeutic Agents”, Exp Opin Ther Patents, 9(6):737-51, (1999).
[cited by applicant]
Saraiva, M. et al., “Interleukin-10 Production by Th1 Cells Requires interleukin-12-induced STAT4 Transcription Factor and ERK MAP Kinase Activation by High Antigen Dose”, Immunity, 31(2):209-19, (2009).
[cited by applicant]
Sato, “Diabetes and Cytokines. Roles of Cytokines in Diabetes Mellitus, Separate Volume”, J Clin Exp Med., cytokine-state of arts, 5 pages, (2004).
[cited by applicant]
Sato, K. et al., “Marked Induction of c-Maf Protein During Th17 Cell Differentiation and Its Implication in Memory Th Cell Development”, J Biol Chem . . . 286(17):14963-71, (2011).
[cited by applicant]
Scaldaferri, F. et al., “Mucosal Biomarkers in Inflammatory Bowel Disease: Key Pathogenic Players or Disease Predictors?” World J Gastroenterol., 16(21 ):2616-25, (2010).
[cited by applicant]
Schamel, W. et al., “Organization of the Resting TCR in Nanoscale Oligomers ”, Immunol Rev., 251(1):13-20, (2013).
[cited by applicant]
Schirle, M. et al., “Combining Computer Algorithms With Experimental Approaches Permits the Rapid and Accurate Identification of T Cell Epitopes From Defined Antigens”, J Immunol Meth., 257(1-2):1-16, (2001).
[cited by applicant]
Schlesinger, S. et al., “Alphavirus Vectors for Gene Expression and Vaccines”, Curr Opin Biotechnol., 10(5):434-9, (Abstract only), (1999 ).
[cited by applicant]
Schlichtholz, B. et al., The Immune Response to p53 in Breast Cancer Patients Is Directed Against Immunodominant Epitopes Unrelated to the Mutational Hot Spot, Cancer Res., 52(22):6380-4, (1992).
[cited by applicant]
Schneider, K. et al., “The End of the Era of Generosity? Global Health Amid Economic Crisis”, Philos Ethics Humanit Med., 4:1, (2009).
[cited by applicant]
Schnütgen, F. et al., “A Directional Strategy for Monitoring Cre-mediated Recombination at the Cellular Level in the Mouse”, Nat Biotechnol., 21(5):562-6, (2003).
[cited by applicant]
Schreiber, H. et al., “Using Carbon Magnetic Nanoparticles to Target, Track, and Manipulate Dendritic Cells”, J Immunol Methods, 356(1-2):47-59, (2010).
[cited by applicant]
Scott, R. et al., “Synthesis, Characterization, and Applications of Dendrimer-Encapsulated Nanoparticles”, J Phys Chem B., 109(2):692-704, (2005).
[cited by applicant]
Serra, P. et al., “Nanoparticle-based Approaches to Immune Tolerance for the Treatment of Autoimmune Diseases”, Eur J Immunol., 48(5):751-6, (2018).
[cited by applicant]
Serreze, D. et al., “Autoreactive Diabetogenic T-cells in NOD Mice Can Efficiently Expand From a Greatly Reduced Precursor Pool”, Diabetes, 50(9):1992-2000, (2001).
[cited by applicant]
Shanks, N. et al., “Are Animal Models Predictive for Humans?”, Philos Ethics Humanit Med., 4(2):1-20, (2009).
[cited by applicant]
Shao, K. et al., “Nanoparticle-Based Immunotherapy for Cancer”, ACS Nano., 9(1):16-30, (2015).
[cited by applicant]
Sherman, E. et al., “Functional Nanoscale Organization of Signaling Molecules Downstream of the T Cell Antigen Receptor”, Immunity, 35(5):705-20, (2011).
[cited by applicant]
Shimoda, S. et al., “Identification and Precursor Frequency Analysis of a Common T Cell Epitope Motif in Mitochondrial Autoantigens in Primary Biliary Cirrhosis”, J Clin Invest., 102(10):1831-40, (1998).
[cited by applicant]
Shukla, S. et al., “Emerging Nanotechnologies for Cancer Immunotherapy”, Exp Bioi Med (Maywood)., 241(10):1116-26, (2016).
[cited by applicant]
Sibley. R. et al., “Recurrent Diabetes Mellitus in the Pancreas Iso− And Allograft. A Light and Electron Microscopic and Immunohistochemical Analysis of Four Cases”, Lab Invest., 53(2):132-44, (1985).
[cited by applicant]
Singha, S. et al., “Peptide-MHC-based Nanomedicines for Autoimmunity Function as T-cell Receptor Microclustering Devices”, Nat Nanotechnol., 12(7):701-10, (2017).
[cited by applicant]
Sollid, L. et al., “Nomenclature and Listing of Celiac Disease Relevant Gluten T-cell Epitopes Restricted by HLA-DQ Molecules”, Immunogenetics, 64(6):455-60, (2012).
[cited by applicant]
Somoza, N. et al., “Pancreas in Recent Onset Insulin-Dependent Diabetes Mellitus. Changes in HLA, Adhesion Molecules and Autoantigens, Restricted T Cell Receptor V Beta Usage, and Cytokine Profile”, J Immunol., 153(3):1…
[cited by applicant]
Spada, F. et al., “Self-recognition of CD1 by Gamma/Delta T Cells: Implications for Innate Immunity”, J Exp Med., 191(6):937-48, (2000).
[cited by applicant]
Spensieri, F. et al., “Human Circulating influenza-CD4+ ICOS1+IL-21+ T Cells Expand After Vaccination, Exert Helper Function, and Predict Antibody Responses”, Proc Natl Acad Sci USA, 110(35):14330-5, (2013).
[cited by applicant]
Sprent, J. et al., “T Cell Death and Memory”, Science, 293(5528):245-8, (2001).
[cited by applicant]
Sprent, J. et al., “T Cell Memory”, Annu Rev Immunol., 20:551-79, (2002).
[cited by applicant]
Standifer, N. et al., “Identification of Novel HLA-A*0201-restricted Epitopes in Recent-Onset Type 1 Diabetic Subjects and Antibody-Positive Relatives”, Diabetes, 55(11):3061-7, (2006).
[cited by applicant]
Steenblock, E. et al., “A Comprehensive Platform for Ex Vivo T-cell Expansion Based on Biodegradable Polymeric Artificial Antigen-Presenting Cells”, Mol Ther., 16(4):765-72, (2008). (2008).
[cited by applicant]
Stratmann, T. et al., “Susceptible MHC Alleles, Not Background Genes, Select an Autoimmune T Cell Reactivity”, J Clin Invest., 112(6):902-14, (2003).
[cited by applicant]
Stratmann, T. et al., “The I-Ag7 MHC Class II Molecule Linked to Murine Diabetes Is a Promiscuous Peptide Binder”, J Immunol., 165(6):3214-25, (2000).
[cited by applicant]
Sukhorukov, G. et al., Stepwise Polyelectrolyte Assembly on Particle Surfaces: A Novel Approach to Colloid Design, Polymers Adv Tech., 9(10-11):759-67, (1998).
[cited by applicant]
Sutton, I. et al., “Primary Biliary Cirrhosis: Seeking the Silent Partner of Autoimmunity”, Gut, 50(6):743-6), (2002).
[cited by applicant]
Szczerkowska-Dobosz, A., “Human Leukocyte Antigens as Psoriasis Inheritance and Susceptibility Markers”, Arch Immunol Ther Exp (Warsz)., 53(5):428-33, (2005).
[cited by applicant]
Tait, B. et al., “HLA Antigens and Age at Diagnosis of Insulin-Dependent Diabetes Mellitus”, Hum Immunol., 42(2):116-24, (1995).
[cited by applicant]
Takahashi, F. et al., “Isolation and Characterization of a Colonic Autoantigen Specifically Recognized by Colon Tissue-Bound Immunoglobulin G From Idiopathic Ulcerative Colitis”, J Clin Invest., 76(1):311-8, (1985).
[cited by applicant]
Takaki, T. et al., “HLA-A*0201-restricted T Cells From Humanized NOD Mice Recognize Autoantigens of Potential Clinical Relevance to Type 1 Diabetes”, J Immunol., 176(5):3257-65, (2006).
[cited by applicant]
Tan, J. et al., “Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells”, J Exp Med., 195(12):1523-32, (2002).
[cited by applicant]
Tanimura, K. et al., “B2-Glycoprotein I/HLA Class II Complexes Are Novel Autoantigens in Antiphospholipid Syndrome”, Blood, 125(18):2835-44, (2015).
[cited by applicant]
Tigges, M. et al., “Human Herpes Simplex Virus (HSV)-specific CD8+ CTL Clones Recognize HSV-2-infected Fibroblasts After Treatment With IFN-gamma or When Virion Host Shutoff Functions Are Disabled”, J Immunol., 156(10):…
[cited by applicant]
Toes, R. et al., “Peptide Vaccination Can Lead to Enhanced Tumor Growth Through Specific T-cell Tolerance Induction”, Proc Natl Acad Sci USA, 93(15):7855-60, (1996).
[cited by applicant]
Toma, A. et al., “Recognition of a Subregion of Human Proinsulin by Class I-restricted T Cells in Type 1 Diabetic Patients”, Proc Natl Acad Sci USA, 102(30):10581-6, (2005).
[cited by applicant]
Trenttham, D. et al., “Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis”, Science, 261(5129):1727-30, (1993).
[cited by applicant]